Published in Br J Surg on March 01, 2003
Pathogenesis and clinical management of hereditary non-polyposis colorectal cancer. Br J Surg (2002) 1.45
The intention to hasten death: a survey of attitudes and practices of surgeons in Australia. Med J Aust (2001) 4.06
Adverse events in surgical patients in Australia. Int J Qual Health Care (2002) 2.80
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg (1993) 2.70
Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet (2000) 2.29
Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut (2002) 1.81
Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum (1993) 1.64
Hereditary non-polyposis colorectal cancer and the role of hPMS2 and hEXO1 mutations. Clin Genet (2004) 1.59
Development of duodenal cancer in a patient with familial adenomatous polyposis. J Gastroenterol (2000) 1.41
Relationship between colorectal and prostate cancer. Dis Colon Rectum (1995) 1.38
Surgical polypectomy of duodenal adenomas in familial adenomatous polyposis: experience of two European centres. Br J Surg (1993) 1.32
Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology (1996) 1.29
Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet (1995) 1.25
Upper gastrointestinal pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. J Clin Pathol (1990) 1.20
A modifying locus for familial adenomatous polyposis may be present on chromosome 1p35-p36. J Med Genet (1996) 1.13
Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. J R Soc Med (1994) 1.04
DNA adducts, detected by 32P-postlabelling, in DNA treated in vitro with bile from patients with familial adenomatous polyposis and from unaffected controls. Carcinogenesis (1993) 1.03
An updated mutation spectrum in an Australian series of PJS patients provides further evidence for only one gene locus. Clin Genet (2006) 0.99
Familial adenomatous polyposis: more evidence for disease diversity and genetic heterogeneity. Gut (2001) 0.97
The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavonoid Naringenin. Colorectal Dis (2003) 0.97
Pouch adenomas in patients with familial adenomatous polyposis. Br J Surg (1993) 0.94
STK11 status and intussusception risk in Peutz-Jeghers syndrome. J Med Genet (2006) 0.93
Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients. Clin Genet (2002) 0.93
Duodenal cancer in polyposis patients. Gastroenterology (1992) 0.90
DNA adducts detected by 32P-postlabelling, in the intestine of rats given bile from patients with familial adenomatous polyposis and from unaffected controls. Carcinogenesis (1992) 0.90
Iatrogenic pancreatitis in familial adenomatous polyposis. Gut (1993) 0.89
Upper intestinal surveillance in familial adenomatous polyposis. Eur J Cancer (1995) 0.89
Can we safely delay or avoid prophylactic colectomy in familial adenomatous polyposis? Br J Surg (1996) 0.87
A programme for reducing smoking in pre-operative surgical patients: randomised controlled trial. Anaesthesia (2005) 0.85
Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Br J Surg (1996) 0.85
Preventive measures in Peutz-Jeghers syndrome. Fam Cancer (2001) 0.85
Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Dis Colon Rectum (2001) 0.84
Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum (1996) 0.83
Follow-up in familial adenomatous polyposis. Lancet (1993) 0.81
Bile acids do not form adducts when incubated with DNA in vitro. Carcinogenesis (1994) 0.81
Malignant change in a duodenal adenoma in familial adenomatous polyposis: report of a case. Am J Gastroenterol (1998) 0.80
Hereditary colorectal cancer: keeping it in the family--the bowel cancer story. Intern Med J (2002) 0.80
Gastroduodenal lesions in familial adenomatous polyposis. Surg Today (2000) 0.80
p53 and K-ras status in duodenal adenomas in familial adenomatous polyposis. Br J Surg (1997) 0.79
Gallbladder dysplasia in patients with familial adenomatous polyposis. Br J Surg (1994) 0.79
Audit of surgeon awareness of readmissions with venous thrombo-embolism. Intern Med J (2003) 0.79
Sulforaphane inhibits growth of a colon cancer cell line. Colorectal Dis (2004) 0.79
Genes and carcinogens. Lancet (1989) 0.79
Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis. Dis Colon Rectum (2001) 0.78
Familial adenomatous polyposis and duodenal lymphoma: report of a case. Dis Colon Rectum (2003) 0.78
Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome? Clin Genet (2011) 0.77
Risk of extracolonic cancer in familial adenomatous polyposis. Br J Surg (1996) 0.77
The use of 32P-postlabelling in studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Mutat Res (1997) 0.77
High pH reduces DNA damage caused by bile from patients with familial adenomatous polyposis: antacids may attenuate duodenal polyposis. Gut (1995) 0.77
32P-postlabelling studies of target tissues and bile from patients with familial adenomatous polyposis and from unaffected controls. IARC Sci Publ (1993) 0.76
An audit of open and laparoscopic inguinal hernia repair. J Qual Clin Pract (2001) 0.75
Current surgical practice in screening for colorectal cancer based on family history criteria. Br J Surg (1999) 0.75
Colomastology as a subspecialty of surgical oncology. Br J Surg (1995) 0.75
Duodenal polyposis in familial adenomatous polyposis. Scand J Gastroenterol (1999) 0.75
Does more equal less or does less equal more? J Qual Clin Pract (2001) 0.75
Ileo-anal pouch procedure. Aust N Z J Surg (1992) 0.75
Screening and management of familial adenomatous polyposis. Gut (1993) 0.75
Early discharge after surgery for breast cancer. Hotel wards are good option for patients. BMJ (1999) 0.75
Magnetic resonance spectroscopy and breast cancer: comment. Aust N Z J Surg (1999) 0.75
Assessment of a scoring system for breast imaging. Br J Surg (1998) 0.75
Association of congenital hypertrophy of the retinal pigment epithelium with familial adenomatous polyposis. Br J Surg (1990) 0.75
Tumour site, sex, and survival in colorectal cancer. Lancet (2000) 0.75
Bile and the growth of intestinal polyps. Arch Surg (1992) 0.75
A missed breast cancer. Aust N Z J Surg (1996) 0.75
Gall-bladder agenesis and associated anomalies. HPB Surg (1995) 0.75
Apparent nonlinear kinetics of secondary-amine tricyclic antidepressants. Clin Pharm (1984) 0.75
A survey of surgical audit in Australia: whither clinical governance? J Qual Clin Pract (2000) 0.75
Appearance of artefacts when using 32P-postlabelling to investigate DNA adduct formation by bile acids in vitro: lack of evidence for covalent binding. Carcinogenesis (1995) 0.75
Volume of infusion controller and delayed vasopressor effect. Ann Intern Med (1983) 0.75
Large bowel cancer: guidelines and beyond. Med J Aust (1999) 0.75
The functional result of pelvic ileal reservoir in 10 patients with familial adenomatous polyposis. Ann R Coll Surg Engl (1989) 0.75
Management of familial adenomatous polyposis. Baillieres Clin Gastroenterol (1992) 0.75
Surveillance of ampullary adenomas in familial adenomatous polyposis. Lancet (1994) 0.75
Case report: metachronous central nervous system desmoid tumours and thyroid carcinoma in a young familial adenomatous polyposis patient. Fam Cancer (2013) 0.75